HIV治療薬の市場規模、シェア、成長分析、薬剤クラス別、薬剤タイプ別、流通チャネル別、地域別-2025～2032年産業予測

HIV治療薬の世界市場規模は2023年に345億7,000万米ドルとなり、予測期間（2025～2032年）のCAGRは4.4%で、2024年の360億9,000万米ドルから2032年には509億3,000万米ドルに成長する展望です。

HIV感染者の世界の増加により、HIV治療薬市場は力強い成長を遂げると考えられます。先進的治療オプションに対する需要の高まりとともに、HIVに対する認識の高まりが、今後数年間の売上をさらに上昇させると予想されます。抗レトロウイルス療法（ART）の革新は、HIV治療薬の強化開発への多額の投資に支えられ、市場に大きな影響を与えると考えられます。HIVに対する認識と予防に重点を置いた政府の取り組みは、長期的な医薬品販売の支えになると予想される一方、早期検査と診断の重視は製薬企業に新たなビジネス機会をもたらします。しかし、薬剤耐性、副作用、社会的烙印、特定の治療法の高コストといった課題は、2031年以降、市場全体の需要を阻害する可能性があります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主要市場の考察

• 重要成功要因
• 競合の程度
• 主要投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 特許分析

HIV治療薬市場規模：薬剤クラス別&CAGR（2025～2032年）

• 市場概要
• 多剤併用薬
• ヌクレオシドアナログ逆転写酵素阻害剤（NRTI）
• 非ヌクレオシド系逆転写酵素阻害剤（NNRTI）
• 侵入と融合阻害剤
• プロテアーゼ阻害剤（PI）
• インテグラーゼ阻害剤
• 共受容体拮抗薬

HIV治療薬市場規模：薬剤タイプ別&CAGR（2025～2032年）

• 市場概要
• ブランド医薬品
• ジェネリック医薬品

HIV治療薬市場規模：流通チャネル別&CAGR（2025～2032年）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局
• その他

HIV治療薬市場規模&CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他の欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他のラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他の中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主要市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

    主要企業プロファイル

    • Gilead Sciences, Inc.（米国）
    • ViiV Healthcare（英国）
    • Merck & Co., Inc.（米国）
    • Bristol-Myers Squibb Company（米国）
    • AbbVie Inc.（米国）
    • Boehringer Ingelheim International GmbH（ドイツ）
    • F. Hoffmann-La Roche AG（スイス）
    • Cipla Inc.（インド）
    • Teva Pharmaceutical Industries Ltd.（イスラエル）
    • Hetero Drugs（インド）
    • Basilea Pharmaceutica（スイス）
    • Advanz Pharma（英国）
    • Sun Pharmaceutical Industries Ltd.（インド）
    • Aurobindo Pharma（インド）
    • Dr. Reddy's Laboratories（インド）
    • Lupin Limited（インド）
    • Macleods Pharmaceuticals Ltd.（インド）
    • Glenmark Pharmaceuticals（インド）
    • Torrent Pharmaceuticals Ltd.（インド）
    • Zydus Lifesciences Limited（インド）

結論と提言

Global HIV Drugs Market size was valued at USD 34.57 billion in 2023 and is poised to grow from USD 36.09 billion in 2024 to USD 50.93 billion by 2032, growing at a CAGR of 4.4% during the forecast period (2025-2032).

The rising global prevalence of HIV infections is set to drive strong growth in the HIV drugs market. Increased awareness of HIV, alongside growing demand for advanced treatment options, is expected to further elevate sales in the coming years. Innovations in antiretroviral therapy (ART) will significantly influence the market, supported by substantial investment in the development of enhanced HIV therapeutics. Government initiatives focused on HIV awareness and prevention are anticipated to support long-term drug sales, while an emphasis on early testing and diagnostics opens new business opportunities for pharmaceutical companies. However, challenges such as drug resistance, side effects, social stigma, and the high cost of certain treatments may hinder overall demand in the market landscape through 2031 and beyond.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hiv Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hiv Drugs Market Segments Analysis

Global HIV Drugs Market is segmented by Medication Class, Drug Type, Distribution Channel and region. Based on Medication Class, the market is segmented into Multi-class Combination Drugs, Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry & Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors and Coreceptor Antagonists. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hiv Drugs Market

The global HIV drugs market is being propelled by the proactive initiatives launched by governments and public health organizations aimed at enhancing awareness and support for HIV treatment. These programs are designed to increase accessibility to HIV medications for patients worldwide, with a particular focus on aiding individuals in low- to middle-income countries. By improving the reach and availability of these essential drugs, these initiatives are anticipated to significantly benefit affected populations, ultimately contributing to better health outcomes and reduced transmission rates in diverse regions across the globe.

Restraints in the Global Hiv Drugs Market

Drug resistance represents a significant challenge within the global HIV drugs market, posing a serious constraint on its growth prospects. The emergence of drug-resistant HIV strains is primarily driven by inconsistent adherence to prescribed medication regimens. This situation not only narrows treatment options available to patients but also complicates disease management strategies. Furthermore, the necessity for alternative therapies to combat these resistant strains slows down the overall potential for market expansion. As a result, addressing the issue of drug resistance is critical for the sustained development and effectiveness of HIV treatment solutions in the global healthcare landscape.

Market Trends of the Global Hiv Drugs Market

The global HIV drugs market is increasingly leaning towards dual therapy as a strategic trend, with pharmaceutical companies seizing the opportunity to enhance patient outcomes while minimizing side effects associated with traditional antiretroviral treatments. This trend not only addresses the growing demand for reduced toxicity but also alleviates the pill burden that patients face, promoting better adherence to treatment regimens. As regulatory bodies continue to support innovative treatment approaches, dual therapy is positioned to gain traction, allowing companies to expand their business scope and cater to a more health-conscious consumer base, thus reshaping the landscape of HIV management in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global HIV Drugs Market Size by Medication Class & CAGR (2025-2032)

• Market Overview
• Multi-class Combination Drugs
• Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
• Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry & Fusion Inhibitors
• Protease Inhibitors (PIs)
• Integrase Inhibitors
• Coreceptor Antagonists

Global HIV Drugs Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Branded Drugs
• Generic Drugs

Global HIV Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global HIV Drugs Market Size & CAGR (2025-2032)

• North America (Medication Class, Drug Type, Distribution Channel)
  • US
  • Canada
• Europe (Medication Class, Drug Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Medication Class, Drug Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Medication Class, Drug Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Medication Class, Drug Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViiV Healthcare (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Drugs (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Basilea Pharmaceutica (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanz Pharma (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations